Group 1 - The core viewpoint of the article is that Kuaishou's total revenue increased by 12% year-on-year to 39.6 billion yuan, exceeding expectations by 1.8% [1] - The non-GAAP net profit rose by 16% year-on-year to 5.5 billion yuan, also surpassing expectations by 2% [1] - The company plans to increase its capital expenditure budget to seize more opportunities brought by artificial intelligence [1] Group 2 - Management indicated that the group will maintain positive free cash flow throughout the year [1] - Haitong International maintains a target price of 74 HKD for Kuaishou, with a rating of "outperform" [1]

Group 1 - The core viewpoint of the article is that Kuaishou's total revenue increased by 12% year-on-year to 39.6 billion yuan, exceeding expectations by 1.8% [1] - The non-GAAP net profit rose by 16% year-on-year to 5.5 billion yuan, also surpassing expectations by 2% [1] - To capitalize on opportunities presented by artificial intelligence, the company has increased its capital expenditure budget [1] Group 2 - The management indicated that the group will maintain positive free cash flow throughout the year [1] - Haitong International maintains a target price of 74 Hong Kong dollars for Kuaishou, with a rating of "outperform" [1]

Core Viewpoint - Haitong International has updated its financial model for AIA Group following the company's Q4 2025 results, which met market expectations, incorporating year-to-date trends in new business value and investment performance [1] Group 1: Financial Performance - AIA Group's new business value is expected to grow by 14% from 2026 to 2028, driven by improvements in agent productivity, diversification of channels and products, and potential performance improvements in both mainland China and Hong Kong markets [1] Group 2: Target Price and Rating - Haitong International has raised AIA Group's target price from HKD 99.5 to HKD 105 and reiterated its "Outperform" rating [1]

Core Viewpoint - Haitong International has updated its financial model for AIA Group following the company's Q4 2025 results, which met market expectations, incorporating trends in new business value and investment performance year-to-date [1] Group 1: Financial Performance - AIA Group's Q4 2025 results were in line with market expectations [1] - The financial model update reflects the new business value trends and investment performance observed since the beginning of the year [1] Group 2: Future Projections - Haitong International forecasts a 14% growth in new business value (at actual exchange rates) for the years 2026-2028 [1] - This growth is primarily attributed to improvements in agent productivity, diversification of channels and products, and potential performance improvements in both mainland China and Hong Kong markets [1] Group 3: Target Price and Rating - The target price for AIA Group has been raised from HKD 99.5 to HKD 105 [1] - Haitong International maintains a "Outperform" rating for AIA Group [1]

Group 1 - The core viewpoint of the article is that Li Auto (02015.HK) reported a revenue of 28.8 billion RMB in Q4 last year, representing a year-on-year decline of 35%, which is in line with market expectations [1] - The automotive sales revenue was 27.3 billion RMB, down 36% year-on-year, primarily due to a decrease in quarterly delivery volume [1] - Quarterly deliveries were approximately 110,000 units, maintaining a relatively high scale among new energy vehicle manufacturers [1] Group 2 - Haitong International Securities Group has assigned a neutral rating to Li Auto with a target price of 83.29 HKD, reflecting a valuation of 1.3 times the sales ratio for 2026 [1] - In the past 90 days, six investment banks have given a buy rating for the stock, with an average target price of 83.32 HKD [1] - Li Auto's market capitalization is 138.6 billion HKD, ranking fourth in the automotive manufacturing industry [1]

Core Viewpoint - Li Auto (02015) reported a revenue of 28.8 billion RMB in Q4 last year, a year-on-year decline of 35%, which is in line with market expectations [1] Revenue Performance - Automotive sales revenue was 27.3 billion RMB, down 36% year-on-year, primarily due to a decrease in quarterly delivery volume [1] - Quarterly deliveries were approximately 110,000 units, maintaining a relatively high scale among new energy vehicle manufacturers [1] Profitability Analysis - The company's vehicle gross margin decreased from previous highs, with Q4 vehicle gross margin at 16.8% [1] - For the full year of 2025, the company is expected to achieve revenue of 112.3 billion RMB, marking the third consecutive year of revenue exceeding 100 billion RMB while remaining profitable [1] - Non-GAAP net profit is projected at 2.4 billion RMB, a year-on-year decline of 78% [1] Future Outlook - Due to recent sales pressure, profitability is expected to be impacted by factors such as purchase tax subsidies, inventory clearance, and rising raw material costs [1] - Despite a cautious short-term outlook, long-term growth remains promising [1] - Revenue forecasts for 2026 to 2028 are projected at 122.2 billion, 153.8 billion, and 164.6 billion RMB, respectively, with the latter two showing an increase of 12% and new introductions [1]

Group 1 - The overall retail market performance in South China during the 2026 Spring Festival was weak, with a decline in customer traffic and average transaction value being the main factors affecting sales [3] - Consumer travel increased in South China, contributing to the decline in foot traffic in shopping districts [3] - The toy sector remains highly prosperous, with Pop Mart (09992) expected to achieve over 25% growth for the year, driven by strong IP operation capabilities [4] Group 2 - The cosmetics sector showed slight overall growth, but there was a clear divide between foreign and domestic brands, with foreign brands like Dior and MAC recording approximately 10% growth [5] - The restaurant industry exhibited a K-shaped recovery during the Spring Festival, with large dining establishments facing pressure on average transaction values, while fast food and casual dining showed relative stability [6] - The apparel sector's sales remained flat, with growth primarily driven by pre-Festival consumption, and sports brands experiencing a slowdown in same-store sales growth [7] Group 3 - The luggage brand Samsonite (01910) benefited from travel demand, with sales rising approximately 15% year-on-year during January-February 2026 [8] - The jewelry sector saw a decline in customer traffic but benefited from rising gold prices, leading to a high single-digit increase in sales [9]

Group 1 - The overall retail market performance in South China during the 2026 Spring Festival was weak, with a decline in foot traffic and average transaction value being the main factors affecting sales [2] - Five out of the first six days of the Spring Festival saw a year-on-year decline in mall foot traffic, with only one day showing growth, indicating overall performance below internal expectations [2] - Increased travel among consumers in South China is identified as a key reason for the decline in foot traffic in shopping districts [2] Group 2 - The collectible toy sector remains highly prosperous, with Pop Mart (09992) expected to achieve over 25% growth for the year, driven by strong IP operation capabilities and a stable fan base [3] - The cosmetics sector shows mixed performance, with foreign brands like Dior and MAC experiencing approximately 10 percentage points of growth, while domestic brands, except for Mao Geping (01318), show weaker results [3] - Mao Geping is projected to achieve a 20% growth target for the year, supported by stable product quality and effective member acquisition strategies [3] Group 3 - The restaurant industry displayed a K-shaped recovery during the Spring Festival, with large dining establishments facing pressure on average transaction values, declining by about 5-15%, while fast food and small dining formats showed slight growth [4] - Entertainment consumption, represented by cinemas, performed poorly, with box office revenues declining compared to the previous year's Spring Festival, attributed to low-quality films and weak star power [4] Group 4 - The apparel sector's sales remained flat, with growth primarily driven by pre-Spring Festival consumption, characterized by increased average transaction values and higher attachment rates [5] - Samsonite (01910) experienced a year-on-year sales increase of approximately 15% during January-February 2026, benefiting from travel demand during the Spring Festival [5] - The jewelry sector saw sales rise due to increasing gold prices, with brands like Chow Tai Fook and Chow Sang Sang reporting growth driven by investment gold bar sales [5]

Core Viewpoint - Haitong International reports that the main business revenue and profit of CSPC Pharmaceutical Group (01093) have bottomed out, with expectations to return to an upward cycle by 2026 and benefit from the launch of innovative oncology and metabolic products starting in 2027 [1] Group 1: Revenue and Profit Outlook - The potential milestone revenue for CSPC Pharmaceutical Group is estimated at $5.8 billion (approximately RMB 40.6 billion), which is expected to gradually enhance the company's profits over the next 3-5 years [1] - The firm believes that upfront payments and milestone revenues will provide sustainable recurring income for the company, leading to an upward revision of the revenue forecast for authorized products post-2027 [1] Group 2: R&D and Collaboration - CSPC Pharmaceutical Group has achieved seven external collaboration deals in the past two years, with total upfront payments of $1.71 billion and potential milestone revenues exceeding $30 billion [2] - The company has partnered with AstraZeneca three times, highlighting its R&D platform's global influence and value [2] - The firm is optimistic about CSPC's ability to generate regular income through milestone sales and net revenue sharing throughout the drug lifecycle [2] Group 3: Pipeline and Technology - CSPC's small nucleic acid platform has a broad layout, targeting popular liver delivery points such as PCSK9, AGT, and ANGPTL3, and is ahead of domestic peers in development [3] - The company has applied for patents related to lipid delivery and specific siRNA treatments, indicating potential advancements in neurological and ocular delivery technologies [3] - The SYS6010 (EGFR-ADC) has accumulated clinical data from over a thousand patients, showing potential for best-in-class efficacy and safety [4] Group 4: Clinical Developments - The company has initiated a Phase III clinical trial for SYS6010 in China for first-line treatment of non-small cell lung cancer (NSCLC) and plans to advance global Phase III trials [4] - CSPC's in vivo CAR-T product, SYS6055, has received clinical approval in China, representing the first in vivo CAR-T product approved domestically, with potential advantages in cost and accessibility [4] Group 5: Financial Projections - The firm has adjusted revenue forecasts for FY25, FY26, and FY27 to RMB 26.7 billion, 28.9 billion, and 30.6 billion respectively, reflecting changes in the recognition of upfront payments [5] - The net profit forecasts for FY25, FY26, and FY27 have been revised to RMB 4.4 billion, 4.6 billion, and 5.3 billion respectively [6]

Core Viewpoint - Haitong International reports that the main business revenue and profit of CSPC Pharmaceutical Group (01093) have bottomed out, with expectations of returning to an upward cycle by 2026 and benefiting from the launch of oncology and metabolic innovative products starting in 2027 [1] Group 1: Financial Projections - The potential milestone revenue for CSPC Pharmaceutical Group is estimated at $5.8 billion (approximately RMB 40.6 billion), which is expected to enhance the company's profits over the next 3-5 years [1] - Haitong International has adjusted the revenue forecasts for FY25, FY26, and FY27 to RMB 26.7 billion, RMB 28.9 billion, and RMB 30.6 billion respectively [5] - The net profit forecasts for FY25, FY26, and FY27 have been adjusted to RMB 4.4 billion, RMB 4.6 billion, and RMB 5.3 billion respectively [6] Group 2: Research and Development Capabilities - CSPC Pharmaceutical Group has completed seven external cooperation transactions in the past two years, with total upfront payments of $1.71 billion and potential milestone amounts exceeding $30 billion [1] - The company has established a strong research and development platform, evidenced by collaborations with AstraZeneca, indicating its global influence and value [1] - The company is recognized for its small nucleic acid platform, which covers popular liver delivery targets and is ahead of domestic peers in development [2] Group 3: Product Pipeline and Market Potential - The SYS6010 (EGFR-ADC) has accumulated clinical data from over a thousand patients, showing potential as a best-in-class product [3] - The company has initiated a Phase III clinical trial for SYS6010 in China and plans to advance global Phase III trials within the year [3] - CSPC has received the first clinical approval in China for its in vivo CAR-T product, SYS6055, which is expected to have advantages in cost, accessibility, and immediacy compared to traditional CAR-T products [4]